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ABSTRACT
Objective: To measure the risk of perinatal transmission ofHBV in chronic carriers who undergo
amniocentesis.
Methods: This was a prospective, longitudinal study from 1990 to 1995 ofwomen who wereHBV
carriers and underwent amniocentesis. The infants of these women were followed from birth to one
year of age. Maternal data examined included HBV antigen and antibody status, liver function tests
(LFTs) and the amniocentesis report.
Results: Twenty-eight women were identified. Two of 28 neonates were stillborn unrelated to
hepatitis. Five infants were lost to follow-up leaving 21 mother-child pairs to evaluate. All 21
women were chronic HBV carriers at the time of amniocentesis for delivery. No mother had
abnormal LFTs, and only one of 21 women was positive for hepatitis B e antigen (HBeAg).
Thirteen amniocenteses were for advanced maternal age, and four were for abnormal maternal
serum alphafetoprotein (MSAFP) screening. None of the amniocenteses were recorded as bloody,
and the placenta was anterior in 6 of21 procedures. None ofthe 21 infants (95% CI: 0-16.8%) were
positive for HbsAg during the first month of life or at 12 months of age. All infants received HBV
vaccine and HBIG immunoprophylaxis.
Conclusion: The risk of transmission ofHBV to the fetus after amniocentesis in women who are
HBV carriers is low. Immunoprophylaxis in these infants was successful. Infect. Dis. Obstet.
Gynecol. 7:283-286; 1999. (C) 1999Wiley-Liss, Inc.
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epatitis B virus (HBV) is readily transmitted
from mother to infant. The majority of this
transmission occurs to asymptomatic HBV carriers
during labor and delivery. Although the mecha-
nism of infection is uncertain, it is presumed to
result from exposure to maternal blood, maternal
secretions or maternal-fetal transfusion1-s and is
more common in women with the hepatitis B e
antigen,z,s-7 Some authors have found indirect evi-
dence of transplacental passage based on the pres-
ence of hepatitis B surface antigen (HBsAg) in am-
niotic fluid, the very early development of neonatal
disease < month) and the development of hepa-
titis in a neonate whose mother’s HBsAg disap-
peared in the third trimester.4,7 These authors have
suggested that transplacental passage may occur up
to 10% of the time; however the mechanism for
this transmission is not well understood.
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Today, infants of mothers with active HBV in-
fection receive hepatitis B immunoglobulin at birth
and the hepatitis B vaccine series substantially re-
ducing the risk of neonatal transmission.8-1z Fail-
ures of immunoprophylaxis programs (as low as
1%) are usually due to noncompliance with vacci-
nation protocols; however, a few failures (estimated
to be less than 10%) may be due to antepartum
transmission. 1,2,4-7,11
Although the mechanism of antepartum fetal
hepatitis B transmission is not well understood,
there is concern that invasive procedures such as
amniocentesis may increase the risk. Amniocente-
sis can result in disruption of the placenta with fetal
and maternal blood exchange. Additionally, mater-
nal blood from the uterus can be introduced into
the amniotic fluid. It is unknown if fetal swallow-
ing of infected amniotic fluid could lead to infec-
tion. Whether amniocentesis actually increases the
fetal risk of hepatitis B acquisition through these
mechanisms is unknown, and clinical reports are
limited 13,14. In this report, we review our experi-
ence with amniocentesis in a United States popu-
lation of HBV carriers to measure if this procedure
is associated with an increased risk of perinatal
transmission.
SUBJECTS AND METHODS
In 1988 the Dallas County Health Department and
Parkland Hospital began a comprehensive program
to prevent perinatal transmission of HBV. 15-17 This
program includes identification of mothers with
HBV through HBsAG screening in pregnancy. The
serologic diagnosis was confirmed by the presence
of hepatitis B core IgG antibody and the absence of
hepatitis B core IgM antibody. No quantitative
testing for HBV by polymerase chain reaction was
performed.
Infants born to mothers who are HBV carriers
are given hepatitis B immunoglobulin (HBIG) at
birth and started on the hepatitis B vaccine series.
The vaccine series starts within 24 hours of birth,
and continues at one and 6 months of age. Infants
are followed from age 9 to 15 months and tested for
hepatitis B surface antibody (HBsAb) response to
the vaccine. If they are found to have an inad-
equate response and lack HbsAb, a repeat series of
vaccinations is given. The presence of HBsAG in-
dicates a prophylaxis failure.
Since 1990, an ongoing surveillance of maternal
HBV carriers and their infants has been done
jointly by the Health Department and Parkland
Hospital. Women who were HBV chronic carriers
and underwent amniocentesis during a pregnancy
were identified. During this period, there were
101,002 deliveries at Parkland Hospital, and the
HBV carrier rate was 0.6% (data not shown).
Statistical analysis was performed with Epilnfo
6.04a (Centers for Disease Control and Prevention,
Atlanta, GA). Means and exact binomial 95% con-
fidence intervals were calculated.
RESULTS
Six hundred and six women who were HBV
chronic carriers were identified and underwent am-
niocentesis during their pregnancies. Five of the
mothers and their infants were lost to follow-up.
The remaining 23 mothers were chronic HBV car-
riers at the time of amniocentesis and at delivery.
No women had evidence of liver transaminase dys-
function, and only one (5%) was positive for the
hepatitis B e antigen (HBeAg). This incidence of
HBeAg positivity is consistent with our obstetric
population of HBV chronic carriers. One of the 23
infants presented at 32 weeks with hydrops and
hydramnios. As part of the diagnostic work-up, an
amniocentesis was performed. Two days after the
amniocentesis, premature rupture of membranes
with preterm labor occurred and a stillborn, se-
verely hydropic fetus was delivered. The etiology
of the hydrops was never determined, and no au-
topsy was performed. Another of the 23 infants was
born with trisomy 18. The infant left the hospital
with hospice care and died at 42 days of life prior to
obtaining hepatitis B serology.
There were 21 remaining patients with liveborn
infants and complete follow-up. The mean mater-
nal age was 34 years, and 17 patients were over age
35. Fifteen women were black, four were Asian,
and two were Caucasian. The mean gestational age
at amniocentesis was 19.5 weeks. The primary in-
dications for amniocentesis are listed in Table 1.
Thirteen amniocenteses were performed for mater-
nal age 35 years or greater, one amniocentesis was
for abnormal MSAFP and four procedures were
performed in women who were both greater than
35 years of age and had an abnormal MSAFP. One
patient had multiple amniocenteses for Rh disease
and two women had amniocenteses for lecithin-
sphingomyelin (L/S) determinations. No proce-
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TABLE I. Indication and gestational age at the time
of amniocentesis
Indication Gestational age # Patients
Abnormal MSAFP screen 16-20 weeks
Maternal age >35 16-20 weeks 13
Maternal age >35 and 16-20 weeks 4
abnormal MSAFP screen
Rh disease 16,26,29,33 weeks
L/S determination 37 weeks 2
dures were recorded as bloody although 6 of the 21
procedures were performed in women with anterior
placentas.
The mean gestational age at delivery was 38.4
weeks. All infants received HBIG at birth and com-
pleted the full course of the hepatitis B vaccine
series. No infants were positive for HBsAg after
completing the vaccine series when tested at 9 to
15 months of age (95% CI; 0-16.1%).
DISCUSSION
The majority of neonatal transmission of HBV oc-
curs during labor and delivery. 1-z,11,4-5 Current im-
munoprophylaxis regimens which include maternal
HbsAg screening, HBIG at birth and neonatal
HBV vaccination, are effective in preventing most
peripartum transmission.3,8,9-1 With the success of
neonatal prevention programs, attention should
now be given to antepartum transmission, as neo-
natal immunoprophylaxis would likely be ineffec-
tive in fetuses infected prior to labor, in particular,
those fetuses infected remote from delivery. Inva-
sive antepartum procedures such as amniocentesis
may increase the risk of antepartum transmission
due to the possible introduction of maternal in-
fected blood into the fetal circulation or the amni-
otic fluid. Because of the potential risk of transmis-
sion, many have recommended avoiding invasive
antenatal procedures. 18-19
Recent reports from Taiwan 13 and from the
Netherlands 14 have reported the risk ofHBV trans-
mission in women who underwent amniocentesis.
The Taiwan study reports on a group of HBV car-
riers with a high incidence ofHBeAg (28%). This is
a more infectious group of patients than is typically
seen in the United States and in our population of
patients where the incidence of the HBeAg is <
5%. In their study, two cohorts of patients were
examined. In the first cohort, cord blood was com-
pared in 35 HBV carriers who underwent amnio-
centesis with 65 HBV carriers who did not undergo
amniocentesis. There was no difference in the oc-
currence of HBsAg in cord blood (2.9 vs 3.1% re-
spectively). The researchers then compared 32 in-
fants of chronic HBV carriers who underwent am-
niocentesis and completed immunoprophylaxis at
birth with 3454 infants who did not have amnio-
centesis from the Taiwan National HBV Preven-
tion Program. When tested at 9 months to 5 years
of age, no difference was seen in HBV infection
(9.4 vs 11%). Based on these results, the authors
concluded that the risk of HBV infection after am-
niocentesis is low.
The report from the Netherlands described 15
HBV carriers. The group had a lower risk of infec-
tivity than the Taiwan paper with only two (13%)
women having HBeAg at the time of amniocente-
sis. None of the 15 infants were infected with HBV
at birth. All infants received HBIG followed by
vaccination, and all infants had protective levels of
HBsAb at 12 months of age. The authors con-
cluded that the risk of transmission of hepatitis B
from amniocentesis was low in their study popula-
tion. Their conclusions were limited by sample size
and few highly infectious HBeAg positive women.
We reported our experience with 21 women in
the United States who underwent amniocentesis
and had complete follow-up of their infants. In our
cohort, amniocentesis during the second and third
trimester did not result in an increased risk ofHBV
transmission, even though 6 of the 21 procedures
were in women with anterior placentas and one
woman underwent multiple procedures. No neo-
nate was born with congenital HBV infection, and
immunoprophylaxis was successful when tested at
9 to 15 months of age.
Our sample size is small, which resulted in a
95% confidence interval of 0 to 16%. Because of
this wide confidence interval, we cannot say am-
niocentesis does not increase the risk ofHBV trans-
mission. However, to decrease the confidence in-
terval to < 5% would take 72 patients and 16 years
at our hospital. Our findings, when considered with
other reports, suggest that the risk of HBV trans-
mission is low after amniocentesis. Our study
population had a low incidence of HBeAg positiv-
ity, and we cannot make conclusions about the ef-
fect of HBeAg on the risk of transmission.
In summary, amniocentesis in a United States
population of HBV carriers with a low prevalence
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of HBeAg does not appear to increase the risk of
antenatal HBV transmission. Hepatitis B, virus
chronic carriers who are contemplating amniocen-
tesis may be counseled about the observed low risk
of HBV transmission. Women with HBeAg and
high infectivity should be counseled that the risk
for HBV transmission may be higher and is cur-
rently uncertain.
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